Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...

PRESS RELEASEAB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves a combination of therapies, including chemotherapy, hormone therapy, immunotherapy, and different medications that ...

From today, Australians with an aggressive form of prostate cancer will have access to cheaper medicines on the Pharmaceutical Benefits Scheme ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

Talazoparib and enzalutamide combination reduces death risk by 20.4% in mCRPC patients, regardless of HRR status. The combination therapy offers survival benefits without increased toxicity, making it ...

Investigators compared clinical outcomes with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel for mCRPC.

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC) has changed considerably. Persistent androgen receptor (AR) signaling has been identified as a target for ...